CULLINAN THERAPEUTICS, INC.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $44.4M | — | $42.1M | — | — | — | $42.0M |
| SG&A Expense | — | $12.8M | — | $11.6M | — | — | — | $13.6M |
| Operating Income | — | $-57.3M | — | $-53.7M | — | — | — | $-55.6M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-53.7M | — | $-49.7M | — | — | — | $-50.6M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | — | — | — | — | — | — | — |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 64.4M | 64.3M | 61.5M | 61.5M | 60.5M | 60.2M | 59.1M | 59.1M |
| Shares Outstanding (Diluted) | 64.4M | 64.3M | 61.5M | 61.5M | 60.5M | 60.2M | 59.1M | 59.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |